IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial of IO102-IO103 as an investigational agent in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in solid tumors (IOB-022/KN-D38) has been accepted for poster presentation at the ESMO Congress 2023 being held in Madrid from October 20-24, 2023.
